Literature DB >> 3816873

Blood level, distribution, metabolite pattern and excretion of [14C]alinidine in mice and rats.

W D Bechtel, I Richter.   

Abstract

Following oral and intravenous administration the absorption, distribution, metabolite pattern and excretion of [14C]alinidine, a drug with specific bradycardic efficacy, was studied in mice and rats. [14C]alinidine was rapidly and extensively absorbed. The distribution of radio-labelled drug over the entire animal body was rapid as indicated by blood level curves as well as by whole body autoradiography. In both species radioactive compounds were eliminated from blood with half-lives ranging from 5.6 h to 7.4 h. More than 50% of the renally excreted radioactivity was a uniform substance behaving in in TLC and HPLC experiments like the drug administered. From rat urine this compound could be identified as [14C]alinidine using mass spectrometry. In mice and rats no definite substance with clonidine-like chromatographic properties was found. Biliary excretion was demonstrated in both species. The renal portion of the total radioactivity elimination was 67.2-70.1% of the dose administered in mice and 68.1-85.1% in rats. Total excretion was 85.1-101.3% of radioactivity given and was complete 3-4 days after [14C]alinidine administration. No significant differences in pharmacokinetic behavior in mice and rats could be found.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816873     DOI: 10.1007/BF03189845

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  Studies on the distribution and fate of S35-labelled benzylpenicillin in the body.

Authors:  S ULLBERG
Journal:  Acta Radiol Suppl       Date:  1954

2.  Proof of the linearity of the pharmacokinetics of alinidine in man.

Authors:  D Arndts; H Warnkross; K L Rominger; H Justus
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  New aspects in the metabolism of alinidine in man.

Authors:  D Arndts; H J Forster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

4.  N-Allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site.

Authors:  W Kobinger; C Lillie; L Pichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-04       Impact factor: 3.000

5.  Cardiovascular actions of N-allyl-clonidine (ST 567), a substance with specific bradycardic action.

Authors:  W Kobinger; C Lillie; L Pichler
Journal:  Eur J Pharmacol       Date:  1979-09-15       Impact factor: 4.432

6.  Chemistry, pharmacology, and structure-activity relationships with a new type of imidazolines exerting a specific bradycardic action at a cardiac site.

Authors:  H Stähle; H Daniel; W Kobinger; C Lillie; L Pichler
Journal:  J Med Chem       Date:  1980-11       Impact factor: 7.446

7.  Alinidine pharmacokinetics following acute and chronic dosing.

Authors:  D W Harron; D Arndts; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man.

Authors:  D W Harron; K Jady; J G Riddell; R G Shanks
Journal:  J Cardiovasc Pharmacol       Date:  1982 Mar-Apr       Impact factor: 3.105

9.  Pharmacokinetics and metabolism of 14C-labelled alinidine in man and dogs.

Authors:  D Arndts; G Leb; H J Förster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

10.  Haemodynamic and electrophysiologic actions of alinidine in the dog.

Authors:  W Traunecker; A Walland
Journal:  Arch Int Pharmacodyn Ther       Date:  1980-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.